Tucidinostat
- Generic Name
- Tucidinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19FN4O2
- CAS Number
- 1616493-44-7
- Unique Ingredient Identifier
- 87CIC980Y0
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Taipei Medical University Shuang Ho Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT05281276
- Locations
- 🇨🇳
Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan
Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05276713
- Locations
- 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05270200
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guanzhou, Guandong, China
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT05186012
- Locations
- 🇨🇳
Henan Provincial Oncology Hospital, Zhengzhou, Henanan, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Shanghai Jiao Tong University school of medicine Ruijin Hospital, Shanghai, China
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05179213
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2021-12-01
- Target Recruit Count
- 20
- Registration Number
- NCT05140616
- Locations
- 🇨🇳
First Affiliated Hospital,Soochow University, Suzhou, Jiangsu, China
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT05113355
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT05083208
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT05076786
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05068427
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.